NCT01601522

Peanut Allergy Oral Immunotherapy Desensitization

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Hamilton Health Sciences Corporation · Academic / Other
• Sex: All
• Age: 5 Years – 10 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to determine how a type of treatment for peanut allergy known as oral desensitization works in the immune system. Objectives 1. To determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure. 2. To assess quality of life in peanut allergic subjects before and after desensitization. 3. To compare serum metabolites in peanut allergic and non peanut allergic subjects.

Detailed description

Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions, and the only treatment is complete avoidance of peanut. Despite avoidance, the majority of peanut allergic people will accidently ingest peanut. OIT has been shown to desensitize peanut allergic subjects (Hofmann et al. 2009). This would protect patients who have no other treatment, and may even form the basis for true tolerance to peanut in the future. Objectives: 1. To determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure. 2. To assess quality of life in peanut allergic subjects before and after desensitization. 3. To compare serum metabolites in peanut allergic and non peanut allergic subjects.

Conditions

• Peanut Allergy

Interventions

Type	Name	Description
PROCEDURE	Peanut protein	500 mg
PROCEDURE	Oat flour	500 mg Oat flour
DRUG	Antihistamine	Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid

Timeline

• Start date: 2012-02-01
• Primary completion: 2021-09-01
• Completion: 2021-09-01
• First posted: 2012-05-18
• Last updated: 2022-02-02

Locations

1 site across 1 country: Canada